IMPACT SIGNED
Improving DNA Analysis for Correct Healthcare
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0IMPACT project word cloud
Explore the words cloud of the IMPACT project. It provides you a very rough idea of what is the project "IMPACT" about.
Project "IMPACT" data sheet
The following table provides information about the project.
| Coordinator |
SAMPLIX ApS
Organization address contact info |
| Coordinator Country | Denmark [DK] |
| Total cost | 2˙669˙623 € |
| EC max contribution | 1˙868˙736 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-05-01 to 2021-04-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | SAMPLIX ApS | DK (HERLEV) | coordinator | 1˙868˙736.00 |
Map
Project objective
Over the past 10 years DNA sequencing has revolutionized how we apply genetics in personalized healthcare, diagnosis and drug development despite that the sequencing technology comes with numerous shortcomings. Samplix has developed a proprietary technology, Xdrop™, which addresses these shortcomings. Samplix’ technology encompasses state of the art microfluidics, molecular biology and bioinformatics. The Xdrop technology enables scientists and medical personnel to retrieve specific single DNA molecules from a minute amount of biological sample e.g. tumour biopsies, for subsequent DNA sequencing. At the core of the Xdrop technology is the generation of millions of droplets, each droplet constituting a reaction chamber for the sample preparation of single DNA molecules. This is opposed to today’s technology which is based on bulk preparation of sample material for DNA sequencing. Single molecule resolution is key to understanding the complexity of major diseases such as cancer, immunological diseases, mental disorders, etc. The proposed project addresses the need to qualify known market barriers and put measures in place to overcome such market barriers. Samplix has engaged a very experienced management team with an aggregated experience of >50 years in developing and selling products for DNA analysis. Samplix has already established: • 5 test site agreements with leading DNA institutions around the globe • Agreements with leading OEM providers on instrument and consumables • A patent estate of 5 patent families. • Freedom to operate in multibillion € market. At Samplix, we strive at 100 mUSD in revenue and profitability in year five after full commercial launch. To achieve such an ambitious goal, we plan to apply a razor/razor blade sales strategy by installing the instrument “for free” in return for a subscription to consumables Samplix raised 4,5 m€ in May 2018 which brings the total capital raised to 8 m€. A bigger financing round is planned for 2019.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMPACT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IMPACT" are provided by the European Opendata Portal: CORDIS opendata.